The high level of sophistication in cancer treatment has led to a new unsolved problem, differentiating between treatment effect, regrowth and pseudo-progression of the tumour. To address these challenges, the GLINT project aims to develop and bring to the clinic a potentially disruptive new technology that can characterise and image glucose delivery, uptake and metabolism in cancer.

GLINT draws from recent research revealing the sensitivity of a technique named glucose-based chemical exchange saturation transfer (glucoCEST) to detect native (D-glucose) glucose uptake in tumours and that glucose analogues, such as 3-oxy-methyl-D-glucose (3OMG), can be used as potential non-metabolisable tracers using the same technique. It is the project’s goal to bring the combination of native D-glucose and 3-O-methyl-D-glucose as a combined exam to European clinical oncology practice to assess cancer glucose uptake and metabolism in almost all cancer types, thereby providing a wide-ranging new diagnostic tool for one of the most devastating diseases in the world.

Under the lead of University College London, eight partners from within and outside the European Union have joined forces to pursue their common goal of providing an inexpensive, widely available, more comprehensive, non-invasive and radiation-free method that can add to the nuclear medicine techniques currently used for cancer assessment within Europe.

EIBIR is a partner in the project, giving support in the areas of project management, dissemination, knowledge management and exploitation.

Facts and figures

CoordinatorUniversity College London
Number of Partners:8
Start Date: January 1, 2016
End Date: January 1, 2020
Total Funding: €5,797,799

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 667510